Should health insurers cover orphan drugs? Although the clear answer appears to be yes, the issue is tricky. An orphan drug is one which treats a limited number of people. In Europe, this designation generally applies to patients with a disease with an overall prevalence between 5 and 10,000 individuals. In order to incentivize innovators […]
Read the rest of this entry »